<p>This week, Drs Wilkes and Ebell discuss a new meta-analysis of the CV benefit of SGLT-2 inhibitors, which is less dramatic than you might think.</p>

This week, Drs Wilkes and Ebell discuss a new meta-analysis of the CV benefit of SGLT-2 inhibitors, which is less dramatic than you might think.

Episode 5: SGLT2 inhibitors reduce CV mortality

Join primary care physicians Michael Wilkes MD from UC Davis and Mark Ebell MD, MS from Michigan State University as they discuss a new practice changing study every week. Studies are selected for their ability to change our practice as primary care physicians for the better: POEMs = Patient Oriented Evidence that Matters.

Share Episode 5: SGLT2 inhibitors reduce CV mortality

Sign up to save your podcasts

Episode 5: SGLT2 inhibitors reduce CV mortality

Episode 5: SGLT2 inhibitors reduce CV mortality